Topical androgens for alopecia to treat sebum overproduction on the face Product 3/6/2024
The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.
View this post in the Community →
Similar Community Posts Join
5 / 1000+ resultscommunity Clascoterone - what we have right now
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
community When do you think Breezula will be released to the public?
The conversation discusses expectations for the release of Breezula, a new hair loss treatment, and compares it to existing treatments like finasteride. Some believe Breezula could be a game-changer due to fewer side effects, while others await more permanent solutions like hair follicle cloning.
community Clascoterone (Winlevi) now approved in Canada
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
community Breezula hasn't even begun phase 3 trials yet. F*cking hell.
The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.
community Why are there no FDA approved NSAA's yet?
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.
Related Research
6 / 88 results
research Clinical Updates in Hair
Most treatments for hair loss in 1997 were not effective for most people, and maintaining hair growth was difficult.
research Significance of RU58841 as a Therapeutic Agent Affecting Androgen Receptor Molecular Interactions in Human Hair Follicles
RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
research A Controlled Study of the Effects of RU58841, a Non-Steroidal Antiandrogen, on Human Hair Production by Balding Scalp Grafts Maintained on Testosterone-Conditioned Nude Mice
RU58841 significantly increases hair growth rate and initiates more hair cycles, but doesn't affect hair thickness, suggesting it could be a new treatment for baldness.
research Alopecia: The Search for Novel Agents Continues
Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.
research Dose-Dependent and Long-Term Effects of RU58841 (Androgen Receptor Blocker) on Hair Growth in the Bald Stumptailed Macaque
RU58841, an androgen receptor blocker, significantly increased hair density, thickness, and length in monkeys when applied topically daily for several months.
research Evaluation of RU58841 as an Anti-Androgen in Prostate PC3 Cells and a Topical Anti-Alopecia Agent in the Bald Scalp of Stumptailed Macaques
RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.